J&J Subsidiary Submits NDA For Ustekinumab In Japan
This article was originally published in PharmAsia News
Executive Summary
Tokyo-based Johnson and Johnson subsidiary Janssen Pharma April 26 submitted a new drug application for ustekinumab for plaque psoriasis